Home-based oncology transforms practice transformation with clear bagging, protecting Medicare reimbursement, provider control, and lower costs for patients, health systems, and payers.
|Articles|January 15, 2013
Jan Berger, MD, MJ, Addresses Challenges in Oncology Management
"Oncology is a very emotional area," says Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners, Editor-in-Chief, The American Journal of Pharmacy Benefits.
Advertisement
"Oncology is a very emotional area," says Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners, Editor-in-Chief, The American Journal of Pharmacy Benefits. "It is emotional for the payers and it's emotional for the providers because they really fight and struggle to keep their patients not only alive, but to have a great quality of life."
Dr Berger also says payers and providers must be brought together in order to benefit the patient and deliver personalized care.
Advertisement
Related to this article
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
An analysis of AccessHope case reviews found that experts recommended changes in more than 80% of cases. About half were implemented, saving a median of $18,636 per case.
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.
At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.
Mirabegron was not tied to higher obesity-related neoplasm risk vs antimuscarinics in overactive bladder, but all-cause mortality was higher.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
3
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
4
Disability, Economic Toll of Multimorbidity Climb in Older Adults
5